CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 30 in CellCept, Mycophenolate (generic)

  1. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.Read the original story

    Monday Aug 11 | CiteULike

    Hepatitis C virus infection affects around 3% of the world population or approximately 160 million people.


  2. Kidney recipient finds endless headaches in obtaining needed pillsRead the original story

    Jul 25, 2014 | Daily Herald

    Having once offered my close friend Irene a kidney, I am always relieved to find her looking good and healthy when we meet.


  3. Immunosuppressive treatments in multiple sclerosis.Read the original story

    Jul 11, 2014 | CiteULike

    Multiple sclerosis is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive.


  4. Transplant Champ Goes Nuts Begging for Pills: HoelterhoffRead the original story

    Jul 8, 2014 | Bloomberg

    Having once offered my close friend Irene a kidney, I am always relieved to find her looking good and healthy when we meet.


  5. Severe Forms of Ocular Surface DiseaseRead the original story w/Photo

    Jul 3, 2014 | Contact Lens Spectrum

    One of the most commonly observed forms of ocular surface disease affecting the ocular surface ecosystem is keratoconjunctivitis sicca - either aqueous-deficient or evaporative forms.


  6. Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus NephritisRead the original story

    Jun 26, 2014 | Drugs.com

    June 26, 2014- Aurinia Pharmaceuticals, Inc., today announced enrollment of the first patient in its planned Phase 2b clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis .


  7. New guidance on how and when to stop immunosuppressants in lupus patientsRead the original story

    Jun 11, 2014 | PhysOrg Weblog

    A new study presented today at the European League Against Rheumatism Annual Congress showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease.1 Within two years, it was possible to stop the immunosuppressant in about 70% of ... (more)


  8. Veloxis Pharmaceuticals A/S Announces Senior Level Appointments In...Read the original story

    Jun 4, 2014 | BioSpace

    Veloxis Pharmaceuticals A/S Announces Senior Level Appointments In Preparation For U.S. Commercialization Of Envarsus XR /PRNewswire/ -- Veloxis Pharmaceuticals A/S today announced the hiring of senior level management in preparation for potential U.S. commercialization of EnvarsusA XR EnvarsusXR is an extended release formulation of tacrolimus ... (more)


  9. Time-dependent variability in tacrolimus trough blood levels is a...Read the original story

    May 30, 2014 | Kidney International

    Correspondence: S. Joseph Kim, Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, 585 University Avenue, 11C-1183, Toronto, Ontario, Canada M5G 2N2.


  10. Veloxis Announces Senior Level Appointments in Preparation for U.S....Read the original story

    Jun 3, 2014 | GlobeNewswire

    Veloxis Pharmaceuticals A/S today announced the hiring of senior level management in preparation for potential U.S. commercialization of EnvarsusA XR an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients.


  11. Pediatric Idiopathic Nephrotic SyndromeRead the original story

    May 16, 2014 | US Pharmacist

    Tran H. Tran, PharmD, BCPS Assistant Clinical Professor St. John's University, College of Pharmacy & Health Sciences Queens, New York Leah E. Bentley, PharmD, BCPS* Chicago, Illinois * Dr. Bentley is employed by Questcor Pharmaceuticals and owns Questcor Pharmaceuticals stock.


  12. Aurinia Reports First Quarter 2014 Financial ResultsRead the original story

    May 15, 2014 | Hispanic Business

    All securities issued in connection with the Offering are subject to a four month hold period from the date of issuance in accordance with applicable securities law, which expires on Aurinia is using the net proceeds from the Offering primarily to advance the development of its lead drug candidate, voclosporin, as a therapy for lupus nephritis and ... (more)


  13. Tianyin Pharmaceutical's (TPI) F3Q 2014 Results - Earnings Call TranscriptRead the original story

    May 15, 2014 | Seeking Alpha

    Ladies and gentlemen, thank you for standing by. Welcome to the Tianyin Pharmaceutical Co., Inc. Third Quarter 2014 Conference Call.


  14. A rare case of cytomegalovirus, scedosporium apiospermum and...Read the original story

    May 13, 2014 | BioMed Central

    Renal transplant recipients are at high risk of developing multiple infections, often concomitantly because of their immunocompromised status.


  15. An update on current pharmacotherapy options in atopic dermatitis.Read the original story

    May 12, 2014 | CiteULike

    Introduction: New knowledge on the pathogenesis of atopic dermatitis gives us new treatment options.


  16. Researchers from Sun Yat Sen University Describe Findings in Monoclonal AntibodiesRead the original story

    Apr 30, 2014 | Hispanic Business

    Monitoring the dynamics of B-cell subsets could enhance understanding of B-cell immunology in clinical transplantation, and may facilitate optimization of current immunosuppressive regimens."


  17. Prompt plasma exchanges and immunosuppressive treatment improves the...Read the original story

    Apr 30, 2014 | Kidney International

    E-mail: arvindbagga@hotmail.com Antibodies to complement factor H are an uncommon cause of hemolytic uremic syndrome .


  18. Survey: Epratuzumab Tops Belimumab in Treatment of SLE PatientsRead the original story

    Apr 28, 2014 | P&T Community

    In a new survey conducted by Decision Resources Group, a health care research firm located in Burlington, Mass., surveyed U.S. and E.U. rheumatologists agreed that new therapies for the treatment of moderate-to-severe systemic lupus erythematosus that offer an improved effect on disease activity and renal organ-domain scores over current therapies ... (more)


  19. Mycophenolate Sodium TabletsRead the original story

    Mar 22, 2012 | ASHP

    Myfortic, Novartis 180 mg tablets, 120 count 360 mg tablets, 120 count March 22, 2012; March 12, 2012; March 7, 2012, University of Utah, Drug Information Service.


  20. Lupus nephritis: maintenance therapy for lupus nephritis--do we now have a plan?Read the original story

    Apr 19, 2014 | CiteULike

    Lupus nephritis increases the morbidity and mortality of patients with SLE. This review compares the randomized, controlled trials that examined various maintenance regimens available to treat LN.